News from contemporarypediatrics.comFollowNews from contemporarypediatrics.comSee all of contemporarypediatrics.com news coverage in one place. Discover how contemporarypediatrics.com’s media bias informs their coverage and compare with thousands of other news outlets.We’ve discovered 136 headlines written by contemporarypediatrics.com during the past 3 months. contemporarypediatrics.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. contemporarypediatrics.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow See all of contemporarypediatrics.com news coverage in one place. Discover how contemporarypediatrics.com’s media bias informs their coverage and compare with thousands of other news outlets. We’ve discovered 136 headlines written by contemporarypediatrics.com during the past 3 months. contemporarypediatrics.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. contemporarypediatrics.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about contemporarypediatrics.comWhere is contemporarypediatrics.com located?contemporarypediatrics.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top contemporarypediatrics.com NewsUnited States · United StatesFirst Brain-Delivered Gene Therapy Approved for AADC Deficiency100% Center coverage: 1 sources(MedPage Today) -- The FDA granted accelerated approval to eladocagene exuparvovec (Kebilidi) to treat children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency, the agency announced Thursday. The treatment is the first approved...See the StoryUnited States · United StatesPress Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - Regeneron Pharmaceuticals (NASDAQ:REGN)100% Center coverage: 1 sourcesDupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade…See the StorySan Francisco, California · San FranciscoNerivio REN wearable now FDA-cleared to treat migraines in children 8 years and upWith this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children.See the StoryLatest News StoriesTopics Most Covered by contemporarypediatrics.comHealthObesityVaccinesHospitalsInfluenzaHealthObesityVaccinesSources Covering Similar Topicshcplive.comPharmacy TimesMedPage TodayManaged Healthcare Executivedermatologytimes.comhcplive.comPharmacy TimesMedPage TodaySuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
